Viruses as nanomedicine for cancer

Narayanasamy Badrinath,1 Jeong Heo,2 So Young Yoo1,3 1BIO-IT Foundry Technology Institute, 2Department of Internal Medicine, College of Medicine, Medical Research Institute, Pusan National University, Busan, 3Research Institute for Convergence of Biomedical Science and Technology, Pusan National Un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Badrinath N, Heo J, Yoo SY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Oncolytic viruses cancer therapy vaccinia virus Virotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b399ba2a3f1a4c229d5b08ab049a49e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b399ba2a3f1a4c229d5b08ab049a49e1
record_format	dspace
spelling	oai:doaj.org-article:b399ba2a3f1a4c229d5b08ab049a49e12021-12-02T00:07:19ZViruses as nanomedicine for cancer1178-2013https://doaj.org/article/b399ba2a3f1a4c229d5b08ab049a49e12016-09-01T00:00:00Zhttps://www.dovepress.com/viruses-as-nanomedicine-for-cancer-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Narayanasamy Badrinath,1 Jeong Heo,2 So Young Yoo1,3 1BIO-IT Foundry Technology Institute, 2Department of Internal Medicine, College of Medicine, Medical Research Institute, Pusan National University, Busan, 3Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea Abstract: Oncolytic virotherapy, a type of nanomedicine in which oncolytic viruses (OVs) are used to selectively infect and lyse cancer cells, is an emerging field in cancer therapy. Some OVs exhibit a specific tropism for cancer cells, whereas others require genetic modification to enhance their binding with and entry into cancer cells. OVs both kill tumor cells and induce the host’s immune response against tumor cells. Armed with antitumor cellular molecules, antibodies, and/or in combination with anticancer drugs, OVs can accelerate the lysis of cancer cells. Among the OVs, vaccinia virus has been the focus of preclinical and clinical research because of its many favorable properties. In this review, the basic mechanisms of action of OVs are presented, including their entry, survival, tumor lysis, and immune activation, and the latest research in vaccinia virus-based virotherapy and its status as an anticancer nanomedicine in prospective clinical trials are discussed. Keywords: oncolytic viruses, cancer therapy, vaccinia virus, virotherapyBadrinath NHeo JYoo SYDove Medical PressarticleOncolytic virusescancer therapyvaccinia virusVirotherapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 4835-4847 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Oncolytic viruses cancer therapy vaccinia virus Virotherapy Medicine (General) R5-920
spellingShingle	Oncolytic viruses cancer therapy vaccinia virus Virotherapy Medicine (General) R5-920 Badrinath N Heo J Yoo SY Viruses as nanomedicine for cancer
description	Narayanasamy Badrinath,1 Jeong Heo,2 So Young Yoo1,3 1BIO-IT Foundry Technology Institute, 2Department of Internal Medicine, College of Medicine, Medical Research Institute, Pusan National University, Busan, 3Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea Abstract: Oncolytic virotherapy, a type of nanomedicine in which oncolytic viruses (OVs) are used to selectively infect and lyse cancer cells, is an emerging field in cancer therapy. Some OVs exhibit a specific tropism for cancer cells, whereas others require genetic modification to enhance their binding with and entry into cancer cells. OVs both kill tumor cells and induce the host’s immune response against tumor cells. Armed with antitumor cellular molecules, antibodies, and/or in combination with anticancer drugs, OVs can accelerate the lysis of cancer cells. Among the OVs, vaccinia virus has been the focus of preclinical and clinical research because of its many favorable properties. In this review, the basic mechanisms of action of OVs are presented, including their entry, survival, tumor lysis, and immune activation, and the latest research in vaccinia virus-based virotherapy and its status as an anticancer nanomedicine in prospective clinical trials are discussed. Keywords: oncolytic viruses, cancer therapy, vaccinia virus, virotherapy
format	article
author	Badrinath N Heo J Yoo SY
author_facet	Badrinath N Heo J Yoo SY
author_sort	Badrinath N
title	Viruses as nanomedicine for cancer
title_short	Viruses as nanomedicine for cancer
title_full	Viruses as nanomedicine for cancer
title_fullStr	Viruses as nanomedicine for cancer
title_full_unstemmed	Viruses as nanomedicine for cancer
title_sort	viruses as nanomedicine for cancer
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/b399ba2a3f1a4c229d5b08ab049a49e1
work_keys_str_mv	AT badrinathn virusesasnanomedicineforcancer AT heoj virusesasnanomedicineforcancer AT yoosy virusesasnanomedicineforcancer
_version_	1718403948831834112

Viruses as nanomedicine for cancer

Ejemplares similares